HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS)

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $7.00 target price on the stock.

Separately, Ascendiant Capital Markets lifted their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th.

Atossa Therapeutics Stock Up 0.3 %

ATOS stock opened at $0.70 on Wednesday. The company’s fifty day simple moving average is $0.79 and its 200 day simple moving average is $1.11. Atossa Therapeutics has a 12-month low of $0.66 and a 12-month high of $2.31. The firm has a market cap of $87.88 million, a price-to-earnings ratio of -3.18 and a beta of 1.20.

Atossa Therapeutics (NASDAQ:ATOS) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. Research analysts expect that Atossa Therapeutics will post -0.22 earnings per share for the current year.

Hedge Funds Weigh In On Atossa Therapeutics

Large investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its position in shares of Atossa Therapeutics by 30.7% in the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock valued at $68,000 after acquiring an additional 16,853 shares during the period. Intech Investment Management LLC bought a new position in shares of Atossa Therapeutics in the 3rd quarter worth about $29,000. Barclays PLC lifted its holdings in shares of Atossa Therapeutics by 14.5% during the fourth quarter. Barclays PLC now owns 191,954 shares of the company’s stock valued at $181,000 after purchasing an additional 24,236 shares during the last quarter. XTX Topco Ltd increased its position in Atossa Therapeutics by 101.2% during the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after buying an additional 24,951 shares in the last quarter. Finally, Gallagher Capital Advisors LLC purchased a new position in shares of Atossa Therapeutics in the 4th quarter worth about $25,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.